Podcasts about Cirrhosis

Send us a textDr. Mitchell Rothstein goes over the FibroScan, a liver scanning technology that produces fast and cheap measurements of liver fat content and fibrosis. Dr. Rothstein reviews what the FibroScan is, how it works, the process of getting a FibroScan, and what the results mean. The doctor explains when you should get a FibroScan, what to expect from the process, and the accuracy compared to invasive liver biopsies.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Welcome to the Atomic Anesthesia podcast hosted by CRNA professor Dr. Rhea Temmermand and Co-Founder Sachi Lord. On this show, you'll hear clear, clinically grounded discussions designed for nurse anesthesia residents and CRNAs who want to feel more confident in complex pharmacology, physiology, and real-world anesthesia decision-making.⚠️ SIGN UP FOR OUR FREE NEWSLETTER: [NEWSLETTER SIGN-UP]Topics included in this episode:Cirrhosis pathophysiology and portal hypertension.Compensated vs decompensated cirrhosis risk.Systemic effects: ascites, encephalopathy, coagulopathy, cardiomyopathy.Altered anesthetic drug metabolism and sensitivity.Anesthetic goals: preserve liver perfusion, avoid hypotension/bleeding.

Send us a textKevin's alcoholism hid in plain sight. Raised in a culture where heavy drinking was normalized and rewarded, alcohol slowly became a necessity rather than a choice. Years of bartending and constant access accelerated the damage until his body began to fail — hallucinations, blackouts, internal bleeding, and repeated hospitalizations ending in a diagnosis no one expects: end-stage liver cirrhosis.Now sober and living with a life-limiting illness, Kevin speaks openly about alcoholism, chronic illness, survivor's guilt, and the reality of choosing sobriety when the damage is already done. This conversation is about accountability, faith, and what it means to keep choosing life even when healing doesn't look the way people expect.✅ Check SEIU West✅ Wellness News✅ Bunny Hugs and Mental Health✅ Parenting in the StormCheck out Kevin's channelhttps://www.youtube.com/@UC_gRJxtDoxeQFoWUvIG0TpQ Check out LD's channelhttps://www.youtube.com/@liverdisease-qb6rkSupport the showCheck out the speakeasy podcast Follow Daniel Unmanageable on Facebook Follow Project Sparky We've got fresh merch and it's amazing! Pick yours up HERE For business or speaking inquiries: Daniel@hardknoxtalks.com Follow Hard Knox TalksFacebook: https://www.facebook.com/hardknoxtalkspodcast/Instagram: https://www.instagram.com/hardknoxtalks/TikTok: https://www.tiktok.com/@hardknoxtalks?lang=en Are you getting something from our content? Tap here and buy us a coffee to say thanks and help us keep this train on the tracks! Check us out on YouTube:https://www.youtube.com/@hardknoxtalksWant to watch our episodes uncensored? Become a channel member here!

Physician-scientist Randall Stafford studies the effects of alcohol use on population health – the true health impact, he emphasizes. Stafford explains how early research suggested that drinking is beneficial – or at least not bad – for people. That mindset produced decades of wishful thinking based on inconsistent science driven by social, emotional, and industry forces. The small cardiovascular benefits, he says, are far outweighed by the risks of cancer, liver disease, depression, and other ills. Although the harms of low-level consumption are small, there is no safe level of alcohol use, Stafford tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: ​​Randall StaffordConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Randall Stafford, a professor of medicine at Stanford University.(00:03:35) Challenges in Alcohol ResearchWhy cultural norms and study limitations complicate evidence.(00:03:56) Historical Perspectives on DrinkingHow early studies suggested benefits and why those conclusions shifted.(00:09:12) Risk, Dose, and Drinking PatternsThe increased risks with binge drinking and higher doses of alcohol.(00:12:15) Health Benefits vs. Lifestyle EnjoymentClarifying what alcohol does—and does not—provide medically.(00:13:37) Alcohol and Mental HealthThe bidirectional effects between alcohol use and mental health.(00:17:37) Broader Mental and Social EffectsAlcohol's connection to bipolar disorder, unemployment, and social harm.(00:20:12) How Alcohol Myths PersistWhy simplified conclusions endured despite contradictory data.(00:22:46) Changing Cultural AttitudesCultural trends toward reduced drinking and alcohol-free periods.(00:25:49) Alcohol and Liver DiseaseThe effects of alcohol beyond heavy use, including metabolic disease.(00:27:29) Strategies to Reduce HarmWay to reduce alcohol consumption and avoid binge drinking.(00:29:25) Future In a MinuteRapid-fire Q&A: avoiding alcohol, research needs, and studying liver disease.(00:31:04) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in as Nancy Reau, MD, reviews key highlights of the most impactful primary biliary cholangitis (PBC) research and gain insights on how to apply these new advances to clinical practice. Topics covered include:Treatment GoalsLong-term Data With PPAR AgonistsInvestigational Therapies for PruritusPresenter: Nancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo download the accompanying slides, visit the program page for this episode: https://bit.ly/4b2d6YD  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today, I'm sitting down with the irrepressible Siggi Clavien, renowned biotech innovator and founder of De-liver-ance, a groundbreaking formula for liver health. Siggi's story is deeply personal—motivated by the loss of loved ones to liver disease, he's made it his life's mission to demystify liver health and help others avoid the fate that touched his own family.   Visit http://loveyourliver.com/NAT code: NAT for 5% off   Episode Timestamps: Introduction and podcast themes ... 00:00:00 Eastern vs. Western liver views ... 00:07:09 Why liver health is central to longevity ... 00:09:28 Hidden toxins: everyday exposures ... 00:12:10 Emotional toxicity and liver ... 00:16:06 Imaging vs. blood tests for liver health ... 00:17:22 Fatty liver trends, risk factors, and children ... 00:20:24 Cirrhosis: new causes, gallbladder link ... 00:25:21 Diet, drugs, and detox ... 00:30:07 Supporting detox daily ... 00:33:39 Fatty liver, metabolism, and key nutrients ... 00:36:41 Liver's impact on mood, brain, hormones ... 00:44:22 Menopause, hormones, and the liver ... 00:47:43 Supplements, packaging, and hidden chemicals ... 00:56:07 Fasting, microplastics, and weight loss stress ... 00:59:29 Deliverance formula: development and benefits ... 01:08:06 Guidance for using Deliverance ... 01:24:04 Core habits: hydration, alcohol, diet soda ... 01:25:39   Our Amazing Sponsors: Blue Peptide Spray from Young Goose: brings the message back loud and clear. With NAD+ APEX to refuel energy, methylene blue to recharge your mitochondria, and GHK-Cu to tell your skin, "Hey, start making that collagen again!" It's longevity science, not cosmetic hype. Visit YoungGoose.com—use code NAT10 to get started, or 5NAT if you're an existing customer.   Fatty15: C15 is 3x more effective than omega-3 and totally vegan. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/NATNIDDAM and using code NATNIDDAM at checkout.   Nature's Marvels from Profound Health: The Thymus Bioregulator helps keep immune response balanced and small human studies in older adults link it with healthier immune markers and fewer seasonal respiratory issues. The Pineal Bioregulator supports your natural melatonin/circadian rhythm—key when schedules and daylight change—so you get the kind of sleep that underpins immune resilience. Head to profound-health.com and use code NAT15 for 15% off your first order.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.Topics covered include:Available agents for second-line treatment of PBC An overview of clinical trial data supporting second-line agents:Obeticholic acid (OCA)BezafibrateElafibranorSeladelparThis episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3rPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help.Topics covered include:Mechanisms of pruritus and fatigue in PBCNonpharmacologic treatment optionsAn overview of clinical trial data supporting second-line agents for symptom management:BezafibrateElafibranorSeladelparInvestigational agents:VolixibatLinerixibatSetanaxibThis episode is the third of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode:https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn how these developments are helping to redefine and elevate treatment goals. Topics covered include:How and when to assess treatment responseRisk factors in PBCBiochemical treatment response and fibrosis stage as predictors of transplant-free survivalDynamics of liver stiffness measurements and clinical outcomes in PBC The importance of bilirubin and alkaline phosphatase normalizationThis episode is the first of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We have a classic episode for you. Update your approach to cirrhosis evaluation and management with Dr. Scott Matherly Associate Professor of Hepatology and Gastroenterology at Virginia Commonwealth University  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro, disclaimer, guest bio Case from Kashlak; Definitions Cirrhosis Diagnosis and Initial Evaluation  Cirrhosis Physical Examination  Decompensated Cirrhosis Management  Ascites and TIPS MELD and transplant consideration Outro Credits Written and Produced by: Elena Gibson MD Infographic and Cover Art: Edison Jyang MD Hosts: Paul Williams MD, FACP; Elena Gibson MD     Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Scott Matherly MD  Sponsor: Aura For a limited time, visit AuraFrames.com and get $45 off Aura's best-selling Carver Mat frames - named #1 by Wirecutter -  by using promo code  CURB at checkout.  Sponsor: DoxGPT Check out DoxGPT by Doximity and see how it can simplify your clinical workflow, from patient care to paperwork. Visit doxgpt.com Sponsor: Master Class Head over to MASTERCLASS.com/CURB for the current offer. Sponsor: Continuing Education Company   Visit CMEmeeting.org/curbsiders to learn more and use promo code Curb30

Join expert faculty, Dr Alan Bonder and Dr Stuart Gordon, to learn more about key gaps in PBC management and how these shortfalls can be addressed through identification of appropriate biochemical goals, proper assessment and management of PBC symptoms, and current second-line therapies. Presenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantBeth Israel Deaconess Medical CenterDepartment of GastroenterologyHarvard Medical SchoolBoston, MassachusettsStuart C. Gordon, MD, FAASLDProfessor of MedicineWayne State University School of MedicineProfessor of MedicineMichigan State University College of MedicineHenry Ford HealthDetroit, MichiganLink to full program:https://bit.ly/3M29pI1Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Pediatric and Developmental Pathology, our hosts Dr. Mike Arnold (@MArnold_PedPath) and Dr. Jason Wang speak with Dr. Mukul Vij of the Department of Pathology, Dr. Rela Institute & Medical Centre, Chennai, Tamil Nadu, India and with Dr. Vaibhav Shah, a Pediatric Gastroenterologist and Hepatologist at Gujarat Super Speciality Clinic, Ahmedabad, Gujarat, India. Hear about an uncommon type of childhood cirrhosis that was first described in India, and how the incidence and recognition of this entity has changed over time as we talk about their article in Pediatric and Developmental Pathology: Indian Childhood Cirrhosis: Report of 2 Cases With Review of Literature and Implication of Metallothionein Immunohistochemical Expression   Featured public domain music: Summer Pride by Loyalty Freak

CME credits: 0.25 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/treating-mash-with-compensated-cirrhosis-a-serious-unmet-need/37646/ Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using noninvasive diagnostic tools like FIB-4, VCTE, and Agile 4, clinicians can accurately identify cirrhosis and clinically significant portal hypertension without the need for biopsy. Management focuses on preventing hepatic decompensation through beta-blocker therapy (particularly carvedilol), nutritional optimization, and hepatocellular carcinoma surveillance. Novel therapies such as efruxifermin and resmetirom may reverse fibrosis. This evidence-driven approach aims to improve outcomes in patients with MASH-related compensated cirrhosis.=

Send us a textWelcome back Rounds Table Listeners! We are back today with a Classic Rapid Fire episode. This week, Drs. Mike and John Fralick discuss two recent papers: the effects of spironolactone on heart failure and cardiovascular death in patients undergoing maintenance dialysis, and antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeding. Two papers, here we go!Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial (0:00 – 7:19)Prophylactic Antibiotics for Upper Gastrointestinal Bleeding in Patients With Cirrhosis: A Systematic Review and Bayesian Meta-Analysis (7:20 – 15:08)And for the Good Stuff (15:09 – 17:51):The $500m slugger who helped Canada get to the World SeriesClinical practice guidelines one-pagers coming soon to Trial Files: https://trialfiles.substack.com/Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/you-cant-diagnose-mhe-unless-you-diagnose-cirrhosis/39661/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

Recent advances in primary biliary cholangitis (PBC) care have resulted in a new focus on personalized care and symptom management. Tune in to learn from patient advocate, Maria G. Morais, RN, how you can integrate patient insights and priorities into treatment plans for PBC. Topics covered include:The Canadian PBC Society Survey: Comorbidities and Treatment GoalsDefining and Achieving Goal-Driven Care for PBC Recent Advances in PBC ManagementNewer Agents for Second-line Treatment of PBCPresenters:Maria G. Morais, RNPBC Transplant PatientVP Patient AdvocacyCanadian PBC SocietyToronto, CanadaLink to full program:https://bit.ly/44ySoL3Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice.Topics covered include: Methods of Assessing PBC Disease ProgressionNewer Agents for Second-line Treatment of PBCPrioritizing Symptom Management and Quality of Life With PBC TreatmentPresenters:Christopher L. Bowlus, MDLena Valenta Professor and ChiefDivision of Gastroenterology and HepatologySchool of Medicine University of California Davis Sacramento, CaliforniaSonal Kumar, MD, MPHAssistant Professor of MedicineDivision of Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkLink to full program: https://bit.ly/43nHx6UGet access to all of our new podcasts by subscribing to the CCO Medical Specialties Podcast on Apple Podcasts, Google Podcasts, or Spotify.     Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Contributor: Alec Coston, MD Educational Pearls: Hepatic encephalopathy (HE) is defined as a disruption in brain function that results from impaired liver function or portosystemic shunting. Manifests as various neurologic and psychiatric symptoms such as confusion, inattention, and cognitive dysfunction Although ammonia levels have historically been recognized as important criteria for HE, the diagnosis is ultimately made clinically. An elevated ammonia level lacks sensitivity and specificity for HE Trends in ammonia levels do not correlate with disease improvement or resolution A 2020 study published in the American Journal of Gastroenterology evaluated 551 patients diagnosed with hepatic encephalopathy and treated with standard therapy Only 60% of patients had an elevated ammonia level, demonstrating the limitations of ammonia levels However, a normal ammonia level in a patient with concern for HE should raise suspicion for other pathology. In patients with cirrhosis presenting with neuropsychiatric symptoms, consider HE as the diagnosis after excluding other potential causes of altered mental status (i.e., Seizure, infection, intracranial hemorrhage) The primary treatment is lactulose Works by acidifying the gastrointestinal tract. Ammonia (NH₃) is converted into ammonium (NH₄⁺), which is poorly absorbed and subsequently eliminated from the body Also exerts a laxative effect, further enhancing elimination References: Haj M, Rockey DC. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020 May;115(5):723-728. doi: 10.14309/ajg.0000000000000343. PMID: 31658104. Lee F, Frederick RT. Hepatic Encephalopathy-A Guide to Laboratory Testing. Clin Liver Dis. 2024 May;28(2):225-236. doi: 10.1016/j.cld.2024.01.003. Epub 2024 Jan 30. PMID: 38548435. Vilstrup, Hendrik1; Amodio, Piero2; Bajaj, Jasmohan3,4; Cordoba, Juan1,5; Ferenci, Peter6; Mullen, Kevin D.7; Weissenborn, Karin8; Wong, Philip9. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60(2):p 715-735, August 2014. | DOI: 10.1002/hep.27210 Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z. PMID: 30706420; PMCID: PMC6416238. Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Jorge Chalit, OMS4 Get your tickets to Tox Talks Event, Sept 11, 2025: https://emergencymedicalminute.org/events-2/ Donate: https://emergencymedicalminute.org/donate/  

Liver, Lipids, and the Left Ventricle

BONUS ORIGINAL CONTENT: The introduction and limitations of the drug Addyi, known as the 'female Viagra,' including its side effects and mixed effectiveness; A listener's concerns about liver fibrosis, providing dietary and supplement recommendations for liver health; The impact of plastic exposure on cardiovascular health, emphasizing the widespread and harmful effects of phthalates found in plastics.

On this week's episode of Critical Care Time, Dr. David Dulaney rounds out GI bleeds in the ICU by taking on cirrhosis & variceal bleeds! During this show we discuss the unique challenge associated with managing a patient with cirrhosis - specifically focusing on the coagulopathy of advanced liver disease. We then delve into the nuances associated with managing a variceal bleed, both in terms of the unique critical care elements but also the challenges faced by the endoscopist when trying to saves these patients in extremis. Tune in, leave us a review and most importantly - leave us some feedback! Hosted on Acast. See acast.com/privacy for more information.

We've been told cancer is genetic… or just bad luck. But what if that's not the whole story? In this deeply personal and eye-opening episode, I share the journey of my mom—a nurse, a night-shift worker, and a fighter who passed away just 7 months after her pancreatic and liver cancer diagnosis. For well over a decade, she was told to "watch" elevated liver enzymes while living in a circadian storm of artificial light, disrupted sleep, and minimal sun exposure. Her story—combined with the latest research—is a powerful case study for rethinking cancer as a metabolic disease rooted in mitochondrial dysfunction, circadian disruption, and environmental chaos. Inside this episode: Why blue light and lack of infrared may be more dangerous than we think How 90% of melatonin is made inside your cells—and why that matters The truth about seed oils, vitamin D, and sun exposure The lifestyle “storm” that quietly builds cancer risk What you can do NOW to reset your light, rhythm, and repair systems

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients ​with cirrhosis. Topics covered include:AASLD guideline recommendations for second-line therapy for PBCConsiderations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelparPresenters:Stuart C. Gordon, MD Professor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MD Professor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

Send us a textWelcome back Rounds Table Listeners! Today we're introducing a new format—the first episode in our Trial Files series, where we provide an overview of a recent Trial Files issue. This week, Dr. Mike Fralick discusses three trials included in a recent throwback issue: opioids versus non-opioids for chronic pain; IV albumin for renal impairment and mortality; and omeprazole before endoscopy in patients with GI bleed. Three trials, 9 minutes, here we go!1. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Trial (00:00 - 2:46)2. Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis (2:47 - 4:50)3. Omeprazole before Endoscopy in Patients with Gastrointestinal Bleeding (4:51 - 7:39)What is Trial Files?A free monthly newsletter on practice-changing trials, delivered straight to your inbox-- sign up here! (7:40 - 8:40)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Send us a textDr. Nikhil Kapila joins Dr. Michael Koren on this live MedEvidence! presentation. Dr. Kapila, a liver disease specialist, explains why we can't live without our liver. The doctors review what the liver does, what can cause damage to the liver, and what can go wrong when the liver suffers damage. They also discuss the importance of early testing, treatment options for some conditions, and the importance of clinical research in pushing liver health forward.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

One out of four Americans has Fatty Liver Disease and Doesn't Even Know It. Are you one? with Phil George Series #3: NAFLD ( non alcoholic fatty liver disease) at least one out of 4 Americans have it and don't know they do until they have serious liver damage that can result in Cirrhosis or liver cancer + I can relate this to metabolic syndrome and excess carbs and as always I can explain “Mechanism or Action” or how you get this “silent Killer” Bio: Phil has spent most of his adult life educating and helping clients live a healthier, more fulfilling life. He is a clinical biochemist/certified personal trainer/health coach. As a biochemist, he was trained to understand “the mechanism of action” or what is causing the problem as opposed to just throwing medications at the illness. Many clients/listeners say that Phil makes complicated subjects much easier to understand. He was hired by a veteran's group and gave seminars throughout New England. Phil continues to give seminars to senior centers and other groups in New England. For the past two years Phil has been the host of a popular radio and TV show in Central Massachusetts, WellnessWave Radio,LLC. on WCRN in Boston, MA. Affiliations: Society of Metabolic Health Practitioners Nutrition Coalition Root Cause Practitioners Please feel free to email him at philgeorge@charter.net with any health/nutrition/exercise questions. https://www.wellnesswave.net/ Be sure to tune into his Radio Show “Wellness Wave Radio LLC” on Dreamvisions 7 Radio Network every Wednesday 11am/11pmET Learn more: https://dreamvisions7radio.com/wellness-wave-radio-llc/  Call In and Chat with Deborah during Live Show: 833-220-1200 or 319-527-2638 Learn more about Deborah here:  www.lovebyintuition.com

Jacob has an amazing page on Instagram called feel_sober_good and that's exactly what he shares. In 2023 Jacob almost lost his life due to his alcohol intake. He was diagnosed with Cirrhosis of the liver. Here how he was able to battle through and how he is doing life now and showing others how to live their lives sober!!Support the show

This episode of Vitality Radio is part six in our ongoing listener Q&A series! Jared tackles two powerful topics you've been asking about: how to naturally support healthy liver function when dealing with non-alcoholic fatty liver, and how to spot misleading supplement marketing online. Learn the most common root causes of fatty liver, the subtle signs it may be affecting you, and key lifestyle, dietary, and supplement strategies that can help the liver perform its vital detoxification role. Then, Jared exposes a widespread online scam used to push questionable supplements and shows you how to protect yourself from hype-based marketing.Products:Assimil-8 Digestive EnzymesBack on TractLiverVitalityEndoCleanseAdditional Information:SCAM: https://yoursupplementreview.com/ (changes products, but always promoting Citruna)Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Send us a textThis recording features audio versions of May 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Recurrent Portal Hypertension after Liver Transplant: Impact on Survival and the Role of Transjugular Intrahepatic Portosystemic Shunt Creation in Management ReadNontarget Hemangioma Size Reduction after Bleomycin–Ethiodized Oil Embolization of Primary Hepatic Hemangioma ReadMR–Guided Microwave Ablation for Patients with Cirrhosis Complicated by Small Hepatocellular Carcinoma ReadEmbolotherapy for Pulmonary Arteriovenous Malformations in the Pediatric Population with Hereditary Hemorrhagic Telangiectasias—A Retrospective Case Series ReadEffects of Prophylactic Coil Embolization of Pelvic Arteries on Surgical Outcomes in Hemodynamically Stable Patients with Complex Acetabular Fractures ReadPercutaneous Ablation versus Radiotherapy for Pain Related to Bone and Soft Tissue Malignancies: A Multipayor Database Analysis of Outcomes ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.  Host:Sonya Choe, University of California Riverside School of MedicineAudio editor:Sonya Choe, University of California Riverside School of MedicineOutreach coordinator:Millennie Chen, University of California Riverside School of MedicineAbstract readers:Ahmed Alzubaidi, Wayne State University School of MedicineIpek Midillioglu, Western University of Health Sciences, College of Osteopathic MedicineNate Wright, Warren Alpert Medical School of Brown University Sanya Dhama, University of California Riverside School of MedicineTiffany Nakla, Touro University Nevada College of Osteopathic MedicineKalei Hering, Harvard Medical School SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Hepatitis means inflammation of the liver. The liver is a vital organ that processes nutrients, filters the blood, and fights infections. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common types of viral hepatitis are hepatitis A, hepatitis B, and hepatitis C. ​Hepatitis D, also known as “delta hepatitis,” is a liver infection caused by the hepatitis D virus (HDV). Hepatitis D only occurs in people who are also infected with the hepatitis B virus. Hepatitis D is spread when blood or other body fluids from a person infected with the virus enters the body of someone who is not infected. Hepatitis D can be an acute, short-term infection or become a long-term, chronic infection. Hepatitis D can cause severe symptoms and serious illness that can lead to life-long liver damage and even death. People can become infected with both hepatitis B and hepatitis D viruses at the same time (known as “coinfection”) or get hepatitis D after first being infected with the hepatitis B virus (known as “superinfection”). There is no vaccine to prevent hepatitis D. However, prevention of hepatitis B with hepatitis B vaccine also protects against future hepatitis D infection. ​Hepatitis E is a liver infection caused by the hepatitis E virus (HEV). HEV is found in the stool of an infected person. It is spread when someone unknowingly ingests the virus – even in microscopic amounts. In developing countries, people most often get hepatitis E from drinking water contaminated by feces from people who are infected with the virus. In the United States and other developed countries where hepatitis E is not common, people have gotten sick with hepatitis E after eating raw or undercooked pork, venison, wild boar meat, or shellfish. In the past, most cases in developed countries involved people who have recently traveled to countries where hepatitis E is common. Symptoms of hepatitis E can include fatigue, poor appetite, stomach pain, nausea, and jaundice. However, many people with hepatitis E, especially young children, have no symptoms. Except for the rare occurrence of chronic hepatitis E in people with compromised immune systems, most people recover fully from the disease without any complications. No vaccine for hepatitis E is currently available in the United States. (credits CDC)

This conversation is the opening segment of SurfingMASH's April discussion, in memory of Stephen A. Harrison, on drug development. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. This opening discussion focuses on exciting advances in one drug class (FGF-21s) and, more broadly, on exploring ways to treat cirrhosis. As Naim points out in his opening comment, these two issues— cirrhosis as a challenge and FGF-21s as a possible solution path —intersect in clear and exciting ways. He notes that the FGF-21 efruxifermin has been reported to have significant improvement in patients with cirrhosis, while the FGF-21 pegozafermin has shared positive results in a small cohort of patients. He also notes that a third FGF-21, efimosfermin alfa, has results in advanced non-cirrhotic MASH that suggest potential for similar efficacy in patients with cirrhosis, but this must be studied and confirmed in clinical trials. He mentions that resmetirom may also be showing signs of efficacy in some patients with cirrhosis. The entire package, he says, is a "game changer."Jörn notes that we are having parallel advances in treatment for advanced, non-cirrhotic patients. Sven concurs and comments that we are seeing effects that are not strictly related to metabolic disease. There is exceptional power that we can demonstrate one-level regression in sicker patients. The three agree that, at the same time, we are seeing cirrhosis trials that will lead to outcomes data; outcomes trials in non-cirrhotic medications may not be far away.Roger asks whether we are making progress in treating patients living with decompensated cirrhosis. Sven discusses what we are learning about treating portal hypertension, which is an important benefit unrelated to fibrosis regression. Simply improving portal hypertension will have an impact on endpoints. Naim points out that some ongoing trials include patients with cirrhosis, including survodutide and belapectin. Louise notes it will require "great P.R." to reverse some of the current perceptions about cirrhosis, but that this is "great." Naim states that even today, we have "a lot to offer" patients with portal hypertension or other symptoms of decompensation. As he concludes, he notes that this is underappreciated today. 

00:00:00 - Surf's Up: Season 6 Episode 5Host Roger Green briefly describes this episode's three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:10:39 - Roundtable: A Deep Dive Into Drug Development, Part OneThe opening portion of this month's roundtable centers around two issues: exciting data for FGF-21s and, more generally, treating patients with cirrhosis. Naim Alkhouri sets the tone in his opening comments, which start by focusing on the exciting SYMMETRY data from efruxifermin and then hones in on FGF-21s and resmetirom in cirrhosis. The rest of the conversation features Jörh Schattenberg, Sven Francque and Naim discussing therapies in development for compensated and decompensating cirrhosis.00;24:44 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing ResmetiromNaga joins Roger to discuss the paper Early Experience with resmetirom to treat Metabolic Dysfunction-Associated Steatohepatitis With Fibrosis in a Real-World Setting from his group at Indiana University, which his group authored and Hepatology Communications recently posted. The paper, based on IU Health's experience with its first 113 resmetirom patients, shares the group's practical experience developing processes to work closely with the specialty pharmacies dispensing resmetirom and, finally, concludes that a more engaged patient management strategy might reduce drug discontinuation to a level comparable with clinical trials.  00:47:21 - Expert: Scott Friedman on Gene Therapy, Diversity of Stellate Cell Types, Other Basic Liver ScienceScott and Roger cover a range of basis science topics in a fast-moving 19-minute discussion. It starts with Scott discussing the increasing acceptance that gene therapy is an acceptable way to treat a range of liver diseases, many of which are orphan or ultra-orphan but, in fact, include potential gene therapies for non-cirrhotic MASH and MASH cirrhosis. He notes that in addition to classic gene therapy, which introduces protective gene variants into the systems of patients with the risky variants, gene therapy is now looking to introduce FGF-21 into patients through genetic modification. From there, the conversation covers CAR-T therapy, the increasing ability to identify many different types of stellate cells and the idea that the most effective therapy for eary fibrosis, advanced fibrosis and cirrhosis might require fundamentally different kinds of interventions. The two final elements are the idea that what we now call "MASH" may be several diseases with different etiologies with similar manifestations and a passionate call for all of us to support maintaining NIH funding in whatever ways we can.01:06:45 - Business ReportAs Roger copes with his laryngitis, AI voices deliver an abbreviated business report 

Many people confuse fatty liver disease with cirrhosis. In this podcast, Salinas Valley Health gastroenterologist Vikram Patel, MD, clarifies the distinctions between the two, revealing why early intervention in fatty liver disease is vital to avoid the irreversible consequences of cirrhosis.

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Stephen Chan, Clinical Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong, to discuss groundbreaking trials in hepatobiliary cancers, the role of diet in chronic liver disease, and the future of liver cancer care.  Timestamps:    00:00 – Introduction  02:09 – CARES-310 trial for liver cancer   4:33 – Camrelizumab + rivoceranib versus sorafenib  7:07 – Prevention and early detection of liver cancer   10:30 – Impact of lifestyle and diet on liver disease  12:38 – KEYNOTE-966 trial for biliary tract cancer  14:45 – Alternative strategies for liver cancer treatment  17:14 – Key initiatives of the International Liver Cancer Association  19:26 – Chan's three wishes for healthcare 

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients ​with cirrhosis. Topics covered include:AASLD guideline recommendations for second-line therapy for PBCConsiderations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelparPresenters:Stuart C. Gordon, MD Professor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MD Professor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from February 1-7, 2025.

Joanne Alves e Marcela Belleza convidam Ana Carolina Malvaccini, R3 de Clínica Médica do HCFMUSP, para falar sobre como fazer o diagnóstico de cirrose: quando suspeitar? como confirmar o diagnóstico?Referências:1. Smith, Andrew et al. “Cirrhosis: Diagnosis and Management.” American family physician vol. 100,12 (2019): 759-770.2. Udell JA, Wang CS, Tinmouth J, et al. Does This Patient With Liver Disease Have Cirrhosis? JAMA.2012;307(8):832–842. doi:10.1001/jama.2012.1863. Bonacini, M et al. “Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.” The American journal of gastroenterology vol. 92,8 (1997): 1302-4.4. Lok, Anna S F et al. “Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.” Hepatology (Baltimore, Md.) vol. 42,2 (2005): 282-92. doi:10.1002/hep.207725. Ginès, Pere et al. “Liver cirrhosis.” Lancet (London, England) vol. 398,10308 (2021): 1359-1376. doi:10.1016/S0140-6736(21)01374-X6. Wilson, Rachel, and Donna M Williams. “Cirrhosis.” The Medical clinics of North America vol. 106,3 (2022): 437-446. doi:10.1016/j.mcna.2021.12.001

Update your approach to cirrhosis evaluation and management with Dr. Scott Matherly Associate Professor of Hepatology and Gastroenterology at Virginia Commonwealth University  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro, disclaimer, guest bio Case from Kashlak; Definitions Cirrhosis Diagnosis and Initial Evaluation  Cirrhosis Physical Examination  Decompensated Cirrhosis Management  Ascites and TIPS MELD and transplant consideration Outro Credits Written and Produced by: Elena Gibson MD Infographic and Cover Art: Edison Jyang MD Hosts: Paul Williams MD, FACP; Elena Gibson MD     Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Scott Matherly MD  Sponsor: Rocket Money Cancel your unwanted subscriptions and reach your financial goals faster with Rocket Money. Go to RocketMoney.com/CURB today.  Sponsor: Rosetta Stone Visit rosettastone.com/curbsiders for 50% off unlimited access to 25 language courses for the rest of your life.  Sponsor: Grammarly  Download Grammarly for FREE at grammarly.com/PODCAST.

In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:ELATIVE, a phase III trial of elafibranor for PBCRESPONSE, a phase III trial of seladelpar for PBCASSURE, another phase III trial of seladelpar for PBCPresenter:Sonal Kumar, MD, MPHDirector, Clinical Gastroenterology and HepatologyAssistant Professor of MedicineWeill Cornell Medical CollegeNew York, New YorkLink to full program:https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:ELATIVE, a phase III trial of elafibranor for PBCRESPONSE, a phase III trial of seladelpar for PBCASSURE, another phase III trial of seladelpar for PBCPresenter:Sonal Kumar, MD, MPHDirector, Clinical Gastroenterology and HepatologyAssistant Professor of MedicineWeill Cornell Medical CollegeNew York, New YorkLink to full program:https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Today we welcome back Karla Adkins to share her inspiring journey of freedom from alcohol, faith, and transformation. Karla's story is one of resilience and hope, offering a candid look at her struggles with alcohol, shame, and vulnerability—and how she found freedom through faith and sharing her inspiring story.  Karla reflects on her initial reluctance to share her experiences with liver failure publicly. Hearing how her story touched others gave her the courage to keep sharing, creating a ripple effect of hope for women struggling to control their drinking. Karla dives deep into the challenges of confronting shame, the healing power of vulnerability, and the transformation that comes from building a personal relationship with Jesus. She recounts her battle with liver failure and cirrhosis, her wake-up call to surrender her life to God, and the profound shift from seeing faith as a religion to experiencing it as an intimate relationship.  Together, Christy, Meade, and Karla explore the misconceptions surrounding sobriety and the subtle but dangerous grip alcohol can have on our lives. Karla emphasizes the importance of understanding its impact—not just on our bodies but on our relationships and spiritual health. Karla's testimony highlights how vulnerability can lead to healing—not just for the person sharing, but for everyone who hears it. She encourages listeners to view fear as an opportunity for growth and to take the leap toward freedom, no matter how uncertain the path may seem. Her gratitude for the chance to share her journey shines through, offering a beacon of hope for anyone facing their own struggle with alcohol. Today's episode is a reminder that no struggle is too great, and no story is too small to make an impact. Listen to Karla's first episode with us, here.  Get Karla's book, “And She Came Tumbling Down” here.   JOIN THE BJDW COMMUNITY HERE! https://butjesusdrankwine.com/community Get Christy's Book:  Love Life Sober, A 40 Day Alcohol Fast To Rediscover Your Joy, Improve Your Health and Renew Your Mind http://lovelifesober40dayfast.com   Learn More about Coaching with Christy  Learn More about Coaching with Meade   Connect with us on Instagram! @imnotsoberimfree @lovelifesoberwithchristy @butjesusdrankwine   You can find this episode on YouTube HERE   The creators, hosts, and producers of the But Jesus Drank Wine podcast are not healthcare practitioners and therefore do not give medical, psychological or professional advice nor do they intend for the podcast, any communication on behalf of BJDW or otherwise to be a substitute for such. Additionally, the views and opinions expressed in any mention of and/or linked resources are those of the authors/owners of those resources and do not necessarily reflect the views or opinions of the But Jesus Drank Wine podcast team or guests of the show.

Join us as we review recent practice-changing articles on preventive PCI, andexanet alfa for ICH, aspirin for fatty liver, naltrexone in cirrhosis, pivmecillinam for UTI, cefepime vs pip-tazo, MDRO decolonization, microplastics and MACE, and more! Fill your brain hole with a delicious stack of hotcakes! Featuring Paul Williams (@PaulNWilliamz), Rahul Ganatra (@rbganatra), Nora Taranto (@norataranto) and Matt Watto (@doctorwatto). Claim CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME! Credits Written and Hosted by: Rahul Ganatra MD, MPH; Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewer: Rahul Ganatra MD, MPH; Emi Okamoto MD Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer Preventive PCI Andexanet alfa for ICH Aspirin for MASLD Naltrexone for AUD in cirrhosis Pivmecillinam for UTI MDRO decolonization Cefepime vs pip/tazo Microplastics Pax-NO-vid Outro Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: ACP MKSAP Learn more about ACP MKSAP at acponline.org/acpmksap  Sponsor: Litter Robot  Whisker is currently offering $50 off Litter-Robot bundles. As a special offer to listeners of the show, go tostopscooping.com/CURB and use promo code CURB to save an additional $50 on any Litter-Robot bundle.

More clinical pearls from ACP #IM2024, including emerging infectious diseases in the US (malaria, dengue, super gonorrhea, and a resurgence of syphilis), new C. diff treatments, coagulopathy and cirrhosis, fatty liver disease, HFpEF, peripheral arterial disease, Lp(a) and ApoB, CAR T-cells for autoimmune disease, SGLT2i for gout, and hematology updates. Paul and Watto are joined by Drs. Nora Taranto, Beth Garbitelli, and of course Chris “The Chiu Man” Chiu. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Tropical Diseases: Resurgence of Malaria and Dengue Fever 03:44 Infectious Diseases: Syphilis Rates and New Treatments for C. diff 08:28 Coagulopathy and Cirrhosis: Managing Hemostasis and Portal Vein Thrombosis 11:34 Fatty Liver Disease: Risk Stratification and Treatment 14:59 Cardiology Updates: Cardiovascular Kidney Metabolic Syndrome 31:03 New Medications for Hypertension 32:54 Renal Denervation and Hypertension 33:51 Lp(a) Drugs and Their Potential 36:01 Peripheral Arterial Disease and Claudication 38:10 SGLT2 Inhibitors and Gout 41:50 APO-B and LDL Cholesterol 42:45 Secondary Hypogonadism and Head and Neck Radiation 45:30 VEXAS: A Genetic Autoimmune Condition 49:08 Obesity-Induced Leukocytosis 52:49 CAR T-Cell Therapy in Rheumatologic Diseases Credits Producers/Writers/Show Notes: Matthew Watto MD, FACP; Paul Williams MD, FACP, Nora Taranto MD, Chris Chiu MD, Beth Garbitelli MD CME, Cover Art: Beth Garbitelli MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Nora Taranto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Sponsor: Litter Robot Go to stopscooping.com/CURB and enter promocode CURB to save an EXTRA $50 on any Litter-Robot bundle. Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: Beginly Visit beginlyhealth.com/curbsiders for the job matching platform for every Physician and Advanced Practice Clinician, from training to practice